01 - The Problem
The therapies capable of destroying solid tumours are so potent that, released into the bloodstream, they trigger catastrophic systemic toxicity - cytokine release, organ failure, death. The science is not the obstacle. Control is.
clinical trials of T-cell engaging therapies for solid tumours
approved therapies for solid tumours to date
02 - Our Solution
CAA keeps a therapeutic antibody inert as it travels through the body, then switches it on only inside the tumour. Full potency, zero collateral.
The antibody's active site is masked, rendering it therapeutically silent in circulation - no binding, no toxicity.
The cloaked antibody circulates safely and accumulates at the tumour, guided to the site where treatment is needed.
A tumour-localised trigger uncloaks the antibody in situ, unleashing full therapeutic potency precisely where it matters.
03 - Leadership
Clinical Advisor
Toxicology expert in cancer therapeutics. Steers clinical study design and safety.
We're looking to expand our team as we progress through in‑vitro and in‑vivo to clinical stage. If you're interested in being involved, please message us at careers@precisionitx.com.
04 - Latest news
Three decades of peer-reviewed groundwork underpin the platform. Keep an eye out for upcoming papers.
Press enquiries: hello@precisionitx.com
Investor relations: ir@precisionitx.com
Connect with us on LinkedIn.